Juridisk Institut

Mergers between Generics: How Competition Commission of India promotes Innovation and Access through Merger Control?

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

  • Kalpana Tyagi
Indian pharma industry is popularly known as the pharmacy of the world as
the industry supplies annually over 10% (in terms of volume) of the worldwide
demand for pharma products. This article concentrates on the role of the
Competition Commission of India (CCI) in promoting access and innovation
in the Indian pharma through its merger control regime. Pursuing an interdisciplinary
approach using insights from competition law, economics and
corporate strategy, this article attempts to answer the question whether
inorganic growth enhances efficiencies by helping parties leverage their key
strengths and seek growth in new relevant product and geographic markets
taking into due account the dynamics of the Indian pharma and the core
competencies of the merging parties. This article discusses the theory of harm
and remedies in all the pharma mergers assessed by the CCI till date.
OriginalsprogEngelsk
TidsskriftGlobal Antitrust Review
Vol/bind2018
Nummer11
Sider (fra-til)33-59
Antal sider27
StatusUdgivet - 2018

Se relationer på Aarhus Universitet Citationsformater

ID: 145274046